We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Introgen Therapeutics has reported interim results of its Phase II trial of
INGN 225, its investigational cancer vaccine, in patients with advanced small
cell lung cancer (SCLC) previously treated with chemotherapy.
Guilford Pharmaceuticals has announced findings from a study of Gliadel Wafer
(polifeprosan 20 with carmustine) and temozolomide used in combination to treat
adult patients with newly diagnosed, high-grade malignant glioma.
New data show that treatment with the investigational therapy Alvesco, an inhaled
corticosteroid, significantly reduced oral corticosteroid use in adults with
severe, persistent asthma while maintaining asthma control.
Bentley Pharmaceuticals, a technology-based specialty pharmaceutical and drug
delivery company with a growing branded and generic product line in Europe,
has announced that its 20-mg generic dosage version of omeprazole has been approved
for marketing in the UK.
Spectrum Pharmaceuticals has acquired worldwide exclusive rights to a lucanthone
from Robert Bases, the inventor of a method of treating cancer of the central
nervous system through the administration of lucanthone and radiation.
Taking a statin drug reduces the risk of all types of dementia, including Alzheimer's
disease, by 44 percent, according to a large study of 8,574 patients published
in the current issue of Neurology.
Callisto Pharmaceuticals has announced further details of its planned trial
of Annamycin in adults with relapsed/refractory acute lymphoblastic leukemia
(ALL) patients planned to begin in mid-2005.
Henk Reesink, associate professor of medicine at Academic Medical Center in
Amsterdam, recently presented results of a Phase Ib clinical trial with the
oral hepatitis C virus (HCV) protease inhibitor VX-950, an investigational drug
discovered by Vertex Pharmaceuticals.